Today: 5 February 2026
Subscribe
Browse Category

Biotech News News 11 August 2025 - 17 October 2025

Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision Medicines (PRAX) Stock Skyrockets 180% on Game‑Changing Trial – Analysts See ‘Blockbuster’ Upside

Record Stock Surge on Phase 3 Breakthrough Praxis Precision Medicines shares skyrocketed on October 16, 2025, after the biotech reported game-changing Phase 3 trial results for its essential tremor drug. The stock closed that Thursday at $162.71, up over 183% in a single day Medcitynews. Earlier that morning, Praxis announced that ulixacaltamide – its experimental therapy for essential tremor – had…
17 October 2025
····
Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

SCNX Stock Climbs on Arbli Launch Pills and a daily pill organizer: Arbli’s liquid formulation helps patients (especially children/elderly) who can’t swallow tablets. Scienture’s stock jumped sharply on Oct. 16 after the company formally launched Arbli™ in the U.S. market. In a GlobeNewswire press release that morning, Scienture announced that Arbli™ is now shipping through major pharmaceutical wholesalers nationwide Globenewswire.…
16 October 2025
····
Whitehawk Therapeutics Stock Rockets on AI Partnership – What Investors Need to Know

Whitehawk Therapeutics Stock Rockets on AI Partnership – What Investors Need to Know

Whitehawk’s stock popped dramatically on Oct. 16 after news of the Tempus collaboration. Shares had been around $2 per share in mid-October Stockinvest, but the new AI partnership sent them soaring in early trading. By mid-day Oct. 16, various data sites showed WHWK up roughly 50–67% on the session Investing. (For comparison, it had already gained ~6.6% on Oct. 15…
16 October 2025
····
Theriva Biologics Stock Skyrockets 92% on Cancer Trial Breakthrough – What’s Next for TOVX?

Theriva Biologics Stock Skyrockets 92% on Cancer Trial Breakthrough – What’s Next for TOVX?

Recent Clinical Developments and Pipeline Updates Theriva Biologics – a Rockville, MD-based clinical-stage biotech – has made headlines with promising cancer trial results. On October 13, 2025, the company announced that expanded data from its VIRAGE Phase 2b trial in metastatic pancreatic ductal adenocarcinoma will be presented at the ESMO 2025 Congress on Oct. 20 ts2.tech. In this trial, patients…
16 October 2025
···
Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Sources: Akero Therapeutics investor materials; Novo Nordisk press statements; Reuters, TS2.tech and FierceBiotechnews reports ts2.tech ts2.tech Fiercebiotech; MarketBeat and DirectorsTalk analyst surveys Marketbeat Directorstalkinterviews; Economic Times deal summary Indiatimes Indiatimes; Business Wire legal alert Businesswire Businesswire; and TradingView market data Marketbeat Tradingview.…
9 October 2025
····
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock Rockets on GLP‑1 Boom and New Approvals: Is LLY the Next Trillion‑Dollar Pharma Titan?

In‑Depth Report Introduction Eli Lilly and Company (NYSE: LLY) has become the poster‑child for the emerging class of GLP‑1‑based obesity and diabetes therapies. Its injectable tirzepatide products Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management) have delivered explosive growth, propelling the company’s market capitalization into the high‑hundred‑billion range. On 6 Oct 2025, LLY traded around $840, close to its all‑time highs Marketbeat.…
6 October 2025
···
RGC Stock Skyrockets 11,000% – Inside Regencell Bioscience’s Wild 2025 Ride

RGC Stock Skyrockets 11,000% – Inside Regencell Bioscience’s Wild 2025 Ride

In-Depth Report on RGC Stock as of September 25, 2025 Company Background & Fundamentals Regencell Bioscience’s Hong Kong office. The company is an early-stage biotech leveraging Traditional Chinese Medicine for neurological disorders. Founded in 2014 and listed on Nasdaq in 2021, Regencell focuses on developing natural TCM-based treatments for conditions like ADHD and autism spectrum disorder Marketbeat. It has even…
25 September 2025
····
Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

Breakthrough Trials, FDA Greenlights & Global Health Alerts: Biotech & Health News (Aug 10–11, 2025)

Novartis announced that two Phase III trials, NEPTUNUS-1 and NEPTUNUS-2, met their primary endpoints in Sjögren’s disease, marking the first global Phase III evidence of significant disease activity reduction with ianalumab and its dual B-cell depletion and BAFF signaling blockade. IO Biotech will disclose topline results from its Phase III melanoma trial of Cylembio (IO102-IO103) in combination with Merck’s Keytruda…
11 August 2025
·
1 … 10 11 12

Stock Market Today

  • Super Bowl Prediction Markets Sidestep Sports Betting Bans in California
    February 5, 2026, 7:44 AM EST. Prediction market platforms like Kalshi and Polymarket enable sports wagering in states banning traditional sportsbooks, including California. These platforms let users trade event contracts rather than place conventional bets, creating a legal gray area as they avoid acting as the 'house' while charging fees. Kalshi reported $161 million in Super Bowl market trading volume, a sixfold rise from last year. Critics question if these contracts amount to repackaged gambling, referencing California's century-old law prohibiting betting on sports. Industry advocates argue these markets are federally regulated financial exchanges distinct from traditional sportsbooks, allowing traders to buy and sell positions until outcomes settle. Legal experts suspect courts will allow this activity to continue for years amid regulatory uncertainty.
Go toTop